Imaging Myelin Injury in Amyotrophic Lateral Sclerosis (ALS)
The study, sponsored by Johns Hopkins University, aimed to explore the potential of 7 Tesla MRI as a diagnostic tool for assessing myelin injury in ALS patients. Although the trial was withdrawn, the insights gained could inform future research and development in ALS diagnostics. The ALS market is characterized by a growing demand for innovative diagnostic techniques, particularly those that can predict disease progression. Companies focusing on neurodegenerative diseases may find strategic opportunities in developing imaging technologies or biomarkers that correlate with clinical outcomes, especially as the ALS patient population continues to seek effective management options.
Indication: Amyotrophic Lateral Sclerosis (ALS)
Modality: medical device
Target: Non-invasive imaging of grey and white matter in ALS patients using 7 Tesla MRI.
Sponsor: Johns Hopkins University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 16, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Non-invasive imaging of grey and white matter in ALS patients using 7 Tesla MRI.
View original source fields
Condition raw: Amyotrophic Lateral Sclerosis (ALS)
Condition normalized: Amyotrophic Lateral Sclerosis (ALS)
Modality raw: medical device
Modality normalized: medical device
Target raw: Non-invasive imaging of grey and white matter in ALS patients using 7 Tesla MRI.
Target normalized: Non-invasive imaging of grey and white matter in ALS patients using 7 Tesla MRI.